English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Small cell lung cancer (SCLC) is a highly malignant tumor and can metastasize to the bone marrow. Bone marrow metastasis could cause bone marrow dysfunction, such as anemia, leukopenia, and thrombocytopenia. Chemotherapy might aggravate thrombocytopenia, and therefore, it is not certain whether patients with severe thrombocytopenia due to bone marrow metastasis should be treated with chemotherapy. We report the case of a 70-year-old woman with SCLC who developed severe thrombocytopenia (below 20,000/μL) due to bone marrow metastasis. Chemotherapy restored her platelet count to normal levels. Although she discontinued chemotherapy because of higher brain dysfunction that occurred after prophylactic cranial irradiation, thrombocytopenia could be controlled using chemotherapy throughout her clinical course. Chemotherapy may be carried out safely in patients with severe thrombocytopenia due to bone marrow metastasis of SCLC.

Thrombocytopenia due to bone marrow metastasis of small cell lung cancer that was stabilized by chemotherapy